Navigation Links
PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
Date:8/20/2008

vercoming nonsense mutations as the basis for treating genetic disease," said Stuart W. Peltz, Ph.D., President and Chief Executive Officer of PTC Therapeutics. "Based on these results, we intend to initiate a Phase 2b study later this year to evaluate the clinical benefit of PTC124 in adults and children with nonsense-mutation-mediated CF. Given the potential applicability of PTC124 to multiple genetic disorders, we have a pivotal study of PTC124 for nonsense-mutation Duchenne/Becker muscular dystrophy ongoing and are planning proof-of-concept studies in additional genetic disorders."

The paper entitled "Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial" is available in an advanced online publication of Lancet on Thursday, August 21st (http://www.lancet.com).

About Cystic Fibrosis

Cystic fibrosis (CF) is a life-threatening genetic disease that causes serious lung infections and digestive complications. According to the Cystic Fibrosis Foundation, CF affects approximately 30,000 adults and children in the United States and nearly 70,000 people worldwide. There is a commercially available genetic test to determine if a patient's CF is caused by a nonsense mutation, and it is estimated that nonsense mutations are the cause of CF in approximately 10 percent of patients in the United States and Europe and over 50 percent of patients in Israel. There is currently no available therapy to correct defective CFTR production and function. Instead, available treatments for CF are designed to alleviate the symptoms of the disease. These treatments include chest physical therapy to clear the thick mucus from the lungs, antibiotics to treat lung infections, and a mucus-thinning drug designed to reduce the number of lung infections and improve lung function. In addition, the majority of cystic fibrosis patients take pancreatic enzyme supplements to a
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. PTC124 Featured at Third Annual Congress of Myology
2. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
3. Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows
4. Atrium shows a strong financial performance for its first quarter
5. A Smoking Gene: deCODE Shows How a Single Variant in the Sequence of the Genome Confers Nicotine Dependence and Risk of Lung Cancer and Other Disease
6. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
7. Survey Shows Most Women Cant Separate Fact From Fiction When It Comes to Cervical Cancer Prevention
8. UW paper in Science shows how some solids mimic liquids on nanoscale
9. New research shows that iPods do not interfere with cardiac pacemakers
10. New kind of transistor radios shows capability of nanotube technology
11. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Belmont, MA (PRWEB) May 21, 2013 ... complete tracking to reporting eLearning solution using Tin ... report and dashboard tool. CLD is a leading ... biotech, and medical device companies worldwide. , ... tracking standard that helps learners and trainers more ...
(Date:5/21/2013)... , May 21, 2013 ... Dialysis and Transplant Association) is the biggest congress in ... replacement therapy. Nearly 10,000 participants are in ... the latest research findings. New pioneering studies have been ... "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA ...
(Date:5/21/2013)... New York , May 21, 2013 ... by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products ... Research, IVD Tests) - U.S. Industry Analysis, Size, Share, Growth, ... 2.4 billion in 2011 and is expected to grow ... to reach an estimated value of USD 4.7 billion ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... 12 Two new white papers detailing,sterility ... download from,Microtest ( http://www.microtestlabs.com ). The white ... manufacturers and one which is specialized,for pharmaceutical ... with sterility testing and reviews different testing,methodologies. ...
... Sept. 12 Bionovo, Inc.,(Nasdaq: BNVI ), a pharmaceutical ... drugs in the areas of women,s health and,cancer, announced today ... at A.G. Edwards, 2nd Annual Emerging Growth Conference in New,York. ... ET on Tuesday,September 18, 2007 at the New York Palace ...
... 12 Genstruct Inc., a,biotechnology company translating the ... announced today that its president and,CEO, Dr. Keith ... the Oncology,Clinical Trial Summit in Arlington, Va., September ... panel discussion focused on,"Enhancing Development and Commercial Value ...
Cached Biology Technology:Free White Papers Detail Sterility Testing Essentials for Medical Device, Pharmaceutical Manufacturers 2Bionovo to Present at A.G. Edwards' 2nd Annual Emerging Growth Conference 2007 2Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit 2
(Date:5/21/2013)... an uphill battle? Try staying fit in space, where ... and bone. , That,s the challenge a group of ... three-year, $1.2 million grant from NASA. Their goal is ... missions. , "You could give astronauts the best exercise ... to stick to it, it isn,t going to help," ...
(Date:5/21/2013)... gathering of biomass experts , Where? ... When? 03-07 June 2013 , ... resource assessment, market and policy developments, manufacturing and installation, ... and benefiting from its 2013 edition from a record ... 60 countries, more than 240 plenary and oral presentations, ...
(Date:5/21/2013)... The epigenetic modifications, which alter the way genes ... apparently be detected in the blood of pregnant ... way to foretell depression in the weeks after ... symptoms become debilitating. , The findings of the ... online in the journal Molecular Psychiatry . ...
Breaking Biology News(10 mins):Fueling fitness on the final frontier 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... times, cells sometimes resort to a form of self-cannibalism ... can have a down side, destroying the pancreas by ... swallows a portion of cytoplasm and ferries it to ... allowing hungry cells to recycle molecules, for example. However, ...
... known to be implicated in Crohn,s disease, a form of ... in the journal Nature Genetics , has identified a ... as providing surprising new links between the condition and other ... 1 in 500 and 1 in 1000 people within the ...
... throughout the world, resulting in large-scale ecosystem alteration and ... drought vary from year to year in severity and ... more severe conditions. Many modern varieties of potatoes ... cultivation in the cold, dry Andean Altiplano gave rise ...
Cached Biology News:Complexity of Crohn's disease revealed as 'gene' count tops 30 2Complexity of Crohn's disease revealed as 'gene' count tops 30 3Drought tolerance in potatoes 2Drought tolerance in potatoes 3
... Peptide-Protein Conjugation, ... Bridges, Complex Peptides/Peptidomimetics, Special ... Phosphorylated/Biotinylated Structures, Peptide labeling AMC, ... -99%, fitting your needs, Chromogenic/Flurogenic ...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
...
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
Biology Products: